{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:07:42Z","timestamp":1792192062557,"version":"4.4.0"},"reference-count":49,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2021-YGJC-20"],"award-info":[{"award-number":["2021-YGJC-20"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>BUB1B, a member of the spindle assembly checkpoint family known as BUB1 mitotic checkpoint serine\/threonine kinase B, has been associated with the promotion of tumor progression. Nevertheless, its specific contributions to tumorigenesis remain largely unexplored. This study seeks to offer a systematic and comprehensive analysis of the role of BUB1B in the progression of various cancers, with a particular focus on lung adenocarcinoma, utilizing a range of databases. We investigated BUB1B\u2019s role in pan-cancer using TCGA data, analyzing it with platforms like HPA, TIMER, TISIDB, GEPIA, cBioPortal, GDC, LinkedOmics, and CancerSEA. Additionally, we assessed BUB1B\u2019s impact on lung adenocarcinoma proliferation and migration through CCK-8, wound healing, transwell assays and Western blot analysis. This study found that BUB1B was upregulated in most cancers and was significantly linked to patient prognosis. Its expression correlated with immune cell infiltration and genetic markers of immunomodulators across different cancers. BUB1B was involved in the acute inflammatory response and IgA production pathways but negatively correlated with inflammation in lung adenocarcinoma. Moreover, the siRNA-mediated knockdown of BUB1B resulted in the inhibition of proliferation and migration of lung cancer cells in vitro. This study underscores the potential of BUB1B as a biomarker and a promising therapeutic target for patients with lung adenocarcinoma.<\/jats:p>","DOI":"10.3390\/ijms26052061","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:22:12Z","timestamp":1740568932000},"page":"2061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma"],"prefix":"10.3390","volume":"26","author":[{"given":"Zhenzhen","family":"Hao","sequence":"first","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"An","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Meng","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e002296","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: A phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: A randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-019-0730-9","article-title":"Combination regimens with PD-1\/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The Tumor Microenvironment Innately Modulates Cancer Progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41421-017-0002-1","article-title":"Dual roles of endothelial FGF-2\u2013FGFR1\u2013PDGF-BB and perivascular FGF-2\u2013FGFR2\u2013PDGFR\u03b2 signaling pathways in tumor vascular remodeling","volume":"4","author":"Hosaka","year":"2018","journal-title":"Cell Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-13-46","article-title":"Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer","volume":"13","author":"Berenguer","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-020-18070-y","article-title":"Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity","volume":"11","author":"Grabovska","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e000447","DOI":"10.1136\/jitc-2019-000447","article-title":"Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients","volume":"8","author":"Xiong","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111267","DOI":"10.1016\/j.intimp.2023.111267","article-title":"CircMAPK1 promoted CD8 + T cell infiltration in LUAD by improving the IGF2BP1 dependent CCL5 upregulation","volume":"127","author":"Zhao","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.21037\/tcr-23-968","article-title":"Molecular markers that predict response to combined radiotherapy and immunotherapy in patients with lung adenocarcinoma: A bioinformatics analysis","volume":"12","author":"Sun","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/1759-7714.14888","article-title":"Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach","volume":"14","author":"Yang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1074\/jbc.M114.616490","article-title":"The Cdc20-binding Phe Box of the Spindle Checkpoint Protein BubR1 Maintains the Mitotic Checkpoint Complex During Mitosis","volume":"290","author":"Tian","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.cub.2017.08.033","article-title":"BubR1 Promotes Bub3-Dependent APC\/C Inhibition during Spindle Assembly Checkpoint Signaling","volume":"27","author":"Overlack","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molcel.2015.11.006","article-title":"Targeting Mitosis in Cancer: Emerging Strategies","volume":"60","author":"Thu","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, H., Li, Y., and Lu, H. (2024). Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-67528-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa1006565","article-title":"Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia","volume":"363","author":"Rio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12032-015-0542-x","article-title":"BUB1B promotes multiple myeloma cell proliferation through CDC20\/CCNB axis","volume":"32","author":"Yang","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41392-021-00746-6","article-title":"BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8159","DOI":"10.1002\/cam4.3411","article-title":"BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway","volume":"9","author":"Qiu","year":"2020","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dong, S., Huang, F., Zhang, H., and Chen, Q. (2019). Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Biosci. Rep., 39.","DOI":"10.1042\/BSR20182306"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.7150\/jca.68408","article-title":"Aberrant Expression of BUB1B Contributes to the Progression of Thyroid Carcinoma and Predicts Poor Outcomes for Patients","volume":"13","author":"Yan","year":"2022","journal-title":"J. Cancer"},{"key":"ref_24","first-page":"2211","article-title":"Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer","volume":"9","author":"Fu","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000512446","article-title":"BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma","volume":"99","author":"Sekino","year":"2021","journal-title":"Oncology"},{"key":"ref_26","first-page":"3367","article-title":"The FOXM1\/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma","volume":"38","author":"Ma","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels: Major advancements and challenges","volume":"7","author":"Fancello","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients with Metastatic Esophagogastric Cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.cell.2013.10.015","article-title":"The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes","volume":"155","author":"Kim","year":"2013","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Picard, E., Verschoor, C.P., Ma, G.W., and Pawelec, G. (2020). Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00369"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","article-title":"Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients","volume":"65","author":"Duffy","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41590-024-01821-0","article-title":"Predictability of B cell clonal persistence and immunosurveillance in breast cancer","volume":"25","author":"Sammut","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","article-title":"Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non\u2013Small Cell Lung Cancer","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40425-019-0697-7","article-title":"Natural killer T cell activation increases iNOS+CD206\u2212 M1 macrophage and controls the growth of solid tumor","volume":"7","author":"Paul","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clim.2011.01.009","article-title":"Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer","volume":"140","author":"Motohashi","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","article-title":"Myeloid-derived suppressor cells\u2014New and exciting players in lung cancer","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic. Acids. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic. Acids. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: An integrated repository portal for tumor\u2013immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: Analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic. Acids. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"D900","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: A cancer single-cell state atlas","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic. Acids. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:31Z","timestamp":1760028211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26052061"],"URL":"https:\/\/doi.org\/10.3390\/ijms26052061","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}